KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Common Equity: 2009-2024

Historic Common Equity for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $5.7 billion.

  • Biomarin Pharmaceutical's Common Equity rose 11.88% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 11.88%. This contributed to the annual value of $5.7 billion for FY2024, which is 14.27% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Common Equity is $5.7 billion, which was up 14.27% from $5.0 billion recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Common Equity high stood at $5.7 billion for FY2024, and its period low was $4.1 billion during FY2020.
  • Its 3-year average for Common Equity is $5.1 billion, with a median of $5.0 billion in 2023.
  • Data for Biomarin Pharmaceutical's Common Equity shows a peak YoY skyrocketed of 31.50% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Common Equity stood at $4.1 billion in 2020, then increased by 3.89% to $4.3 billion in 2021, then increased by 7.91% to $4.6 billion in 2022, then rose by 7.57% to $5.0 billion in 2023, then climbed by 14.27% to $5.7 billion in 2024.